The developer of precision vascular robotics announced its CorPath GRX System was successfully used in robotic-assisted coronary interventions.
Daxor’s new technology designed to measure blood volume has the potential to reduce patient readmission rates and improve outcomes for patients suffering from acute heart failure.
The release of the ST LEUIS trial data comes on the heels of Apple receiving FDA clearance for an ECG app for the Apple Watch.
The Santa Clara, CA-based company filed its PMA submission with FDA earlier this year and hopes to be able to launch the technology in the first half of 2019.
FDA has approved the use of Abbott's Heartmate 3 device for advanced heart failure patients who are not eligible for a transplant. These patients will live with their device for the rest of their life.
Abbott Laboratories presented some disappointing data for its bioresorbable stent program at TCT, but it was a different story for Reva Medical's scaffold.
The Minneapolis-based company is developing a low-energy implantable defibrillation therapy designed to more gently restore normal heart rhythm.
The Wayne, PA-based company is picking up Essential Medical to help bolster its presence in the structural heart market.
The Burlington, MA-based company said it has acquired the vascular clot management business of Applied Medical Resources for $14.2 million.
During TCT, the Marlborough, MA-based company revealed results of the IMPERIAL study, which showed its Eluvia stent performed significantly better than Cook Medical’s Zilver PTX.
With TCT in full swing, Or Yehuda, Israel-based Cardiovalve is launching the AHEAD US Multicenter Study, and jumping head first into the quickly growing TMVR market.
LivaNova is launching a pivotal study that will look at how stimulation of the vagus nerve with the VITARIA device can help treat heart failure patients.